FDA Issues First Untitled Letter Of The Year To Xeris Pharmaceuticals
Published:
Jun 20, 2023
The wait is finally over. On June 7, 2023, after remaining silent for over an entire year, the US Food and Drug Administration ("FDA") Office of Prescription Drug Promotion ("OPDP") issued its first untitled letter of 2023 to Xeris Pharmaceuticals, Inc. ("Xeris").1 The untitled letter involved promotional communications for Recorlev® (levoketoconazole) tablets...
Read More
Read More